Followers | 3350 |
Posts | 86036 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Monday, October 07, 2019 6:41:22 AM
News Link:
http://www.globenewswire.com/news-release/2019/10/07/1925687/0/en/BriaCell-Doses-First-Patient-in-Phase-I-IIa-Study-Evaluating-Bria-IMT-in-Combination-with-INCMGA00012-and-Epacadostat-in-Patients-with-Advanced-Breast-Cancer.html
Email Print Friendly Share
October 07, 2019 06:30 ET | Source: BriaCell Therapeutics Corp
Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer.
Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate the cancer cells.
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has initiated dosing in a Phase I/IIa clinical study of its lead product candidate, Bria-IMT™, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer whose disease has progressed following standard of care therapies. No effective treatment options for this patient population currently exists making advanced breast cancer an unmet medical need.
The study design includes an initial group of patients to be treated with the Bria-IMT™ regimen in combination with INCMGA00012 to establish safety. A subsequent group of patients will be treated with the triple combination of the Bria-IMT™ with INCMGA00012 and epacadostat. The starting dose of epacadostat has been established to be safe when given in combination with INCMGA00012 in patients with cancer. The goal is to remove cancer-induced suppression of the immune system (i.e., taking the foot off the brakes that the cancer puts on the immune system) thereby awakening the immune response. This should permit the potent immune responses induced by the Bria-IMT™ regimen (i.e., putting the foot on the gas pedal) to attack the cancer.
“The initiation of Bria-IMT™ clinical study is a major milestone for BriaCell, marking the launch of BriaCell’s first clinical collaboration with Incyte. This Phase I/IIa clinical trial of Bria-IMT™ builds upon the early clinical findings of our novel immunotherapy, as well as biomarker analysis from patients who benefitted the most in our monotherapy trial with Bria-IMT™ versus those who did not,” said Dr. Bill Williams, President & CEO of BriaCell. “Both INCMGA00012 and epacadostat have been shown to reverse cancer-induced suppression of immune cells, making them a rational performance booster for Bria-IMT™ in the clinical study. We are pleased with the initiation of the clinical study and expect to report preliminary safety data in 4Q 2019.”
About the Study
Phase I/IIa clinical trial is an open-label, multi-center study to evaluate the safety and efficacy of Bria-IMT™ in combination with INCMGA00012, and epacadostat in patients with advanced breast cancer. In the initial stage, BriaCell expects to enroll up to 24 patients with advanced breast cancer. The primary endpoint is safety and overall response rate (ORR) and secondary endpoints include duration of response, progression free survival (PFS) and overall survival (OS). Additional analysis will include evaluation of potential predictive biomarkers including HLA. BriaCell expects to report preliminary efficacy and biomarker findings on up to 30 patients.
For further information on the clinical trial, please visit https://clinicaltrials.gov (Identifier: NCT03328026).
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with immune checkpoint inhibitors such as the Incyte drugs INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.
For additional information on BriaCell, please visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Recent BCTX News
- BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients • GlobeNewswire Inc. • 09/18/2024 11:50:00 AM
- BriaCell Therapeutics Announces Closing of $8.5 Million Offering • GlobeNewswire Inc. • 09/12/2024 08:05:05 PM
- BriaCell Therapeutics Announces $8.5 Million Offering • GlobeNewswire Inc. • 09/11/2024 04:09:57 PM
- BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer • GlobeNewswire Inc. • 09/11/2024 11:50:00 AM
- BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer • GlobeNewswire Inc. • 09/10/2024 11:50:35 AM
- BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting • GlobeNewswire Inc. • 09/09/2024 11:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:30:28 PM
- BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer • GlobeNewswire Inc. • 07/18/2024 11:56:26 AM
- BriaCell Presents Clinical Efficacy Data at ASCO 2024 • GlobeNewswire Inc. • 06/03/2024 12:00:32 PM
- BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 • GlobeNewswire Inc. • 05/24/2024 12:00:00 PM
- BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/17/2024 08:33:11 PM
- BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/15/2024 12:00:39 PM
- BriaCell Announces Oral and Poster Presentations at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 12:00:33 PM
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference • GlobeNewswire Inc. • 03/06/2024 01:00:26 PM
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case • GlobeNewswire Inc. • 02/07/2024 01:00:37 PM
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing • GlobeNewswire Inc. • 02/06/2024 01:30:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:24:58 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM